Drug Trial Radar · NCT05143528
Evaluating the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's Disease
Last checked: Nov 19, 2026Latest source record: Dec 3, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,275
Planned (sponsor's estimate)
Start
Feb 1, 2022
Primary completion
Dec 31, 2025
Study completion Jun 1, 2026
Sponsor
- Lead sponsor
- KeifeRx, LLCIndustry
- Sponsor type
- Industry
- Collaborators
- Worldwide Clinical Trials; Life Molecular Imaging GmbH; Sun Pharmaceutical Industries Limited
- First posted
- Dec 3, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 55 years, up to 85 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will investigate the safety and efficacy of a Tyrosine Kinase Inhibitor (TKI) called Nilotinib BE (bioequivalent) in individuals with Early Alzheimer's disease (EAD). This is a multi-center double blinded, Phase 3 study, that will enroll patients for three years in approximately 50 centers nationwide. The total duration of the study will be for five years.
Conditions
- Alzheimer Disease
Interventions
Nilotinib BE 84mgDrug
84 mg capsule
Nilotinib BE 112 mgDrug
112 mg capsule
PlaceboDrug
placebo capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes From Baseline in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) Score at Week 72 [ Time Frame: Baseline, Week 72]Time frame: 72 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.